Baxter International Inc. (NYSE:BAX) Stock Performance: Q2 Earnings Beat and Analyst Upgrade

• Analyst Upgrade & Stock Surge: Citigroup upgraded Baxter International Inc. (NYSE:BAX) from Sell to Neutral, coinciding with a significant stock price increase that brought shares near their 52-week high.
• Strong Financial Performance: Baxter exceeded market expectations in Q2 2026, reporting adjusted earnings per share (EPS) of $0.56 and revenue of $2.96 billion, both beating estimates.
• Positive Outlook & Valuation: The company raised its 2026 sales growth and adjusted EPS guidance, indicating a positive outlook, though GuruFocus suggests Baxter is undervalued despite past profitability challenges.

Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides hospital products and medical devices. Its main activities include developing and selling items for drug compounding, IV solutions, and advanced surgery. Following recent stock market performance, Citigroup has upgraded its rating on Baxter from Sell to Neutral, with the stock priced at $26.75 at the time of the change.

The upgrade coincides with a significant stock price increase. Shares of Baxter surged to close at $26.75 after the company announced strong second-quarter 2026 financial results. This price is near its new 52-week high of $30.00, a large jump from its low of $15.73, showing a strong recovery in investor confidence.

Baxter's financial performance exceeded market expectations. The company reported adjusted earnings per share (EPS) of $0.56, which was 55.6% higher than the estimated $0.36. Adjusted EPS is a measure of profit that removes one-time or irregular items, giving a clearer picture of a company's ongoing operational health.

Revenue growth also showed positive momentum, rising 5% to $2.96 billion and beating estimates. This increase was driven by strong demand in its Drug Compounding and Advanced Surgery segments. As a result, Baxter raised its 2026 sales growth forecast to 3%-4% and its adjusted EPS guidance to a range of $1.95-$2.15.

CEO Andrew Hider expressed encouragement with the financial results, as reported by Benzinga. While GuruFocus data suggests Baxter is undervalued with a GF Value of $34.41, it also advises caution. This is because the company has a history of being unprofitable and having negative cash flow.